Anti-CD4 monoclonal antibody GK1-5

Drug Profile

Anti-CD4 monoclonal antibody GK1-5

Latest Information Update: 17 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Royal Melbourne Hospital; University of Iowa
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Rheumatic disorders; Transplant rejection

Most Recent Events

  • 01 Sep 1998 A preclinical study has been added to the Transplant rejection pharmacodynamics section
  • 15 Apr 1997 No-Development-Reported for Diabetes mellitus (Unknown route)
  • 31 Jul 1996 No-Development-Reported for Rheumatic disorders (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top